Other
Neoplasm by Site
CI-CAN-00000003Explore in graph →
Non-malignant20,494 active trials253 approved drugs3,567 evidence items
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000003Explore in graph →
Clinical trials
92,594 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06182800 | Adebrelimab Combined With Bevacizumab and Docetaxel for Advanced Non-Squamous Non-small Cell Lung Cancer After Progression on First-line Immunotherapy | unknown | Phase 2 | 35 | The First Affiliated Hospital of Xinxiang Medical CollegeOTHER | 0 | Dec 27, 2023 | clinicaltrials |
| NCT03256981 | Stereotactic Body Radiotherapy for the Treatment of OPD(HALT) | unknown | Phase 2 / Phase 3 | 113 | Institute of Cancer Research, United KingdomOTHER |
| 5 |
| Dec 26, 2023 |
| clinicaltrials |
| NCT05820191 | B-amyloid as a Marker for GBM Bioimaging | unknown | Phase 2 | 3 | Universidad Central del CaribeOTHER | 1 | Dec 21, 2023 | clinicaltrials |
| NCT06178601 | A Study of RC48-ADC Combined With Cadonilimab（AK104）in the Treatment of HER2-expression Locally Advanced or Metastatic Urothelial Carcinoma | unknown | Phase 2 | 36 | Shanxi Province Cancer HospitalOTHER | 1 | Dec 21, 2023 | clinicaltrials |
| NCT04329429 | A Study of RC48-ADC in Subjects With HER2 Overexpressed Metastatic Biliary Tract Cancer | unknown | Phase 2 | 57 | RemeGen Co., Ltd.INDUSTRY | 1 | Dec 20, 2023 | clinicaltrials |
| NCT06170697 | Advanced First-line Treatment of Short-term Postoperative Progression of Head and Neck Squamous Cell Carcinoma | unknown | Phase 2 | 46 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Dec 20, 2023 | clinicaltrials |
| NCT05757466 | Prolgolimab Monotherapy or in Combination With Bendamustine for r/r Classical Hodgkin Lymphoma(Prolgo-HL) | unknown | Phase 2 | 30 | St. Petersburg State Pavlov Medical UniversityOTHER | 1 | Dec 19, 2023 | clinicaltrials |
| NCT05839197 | A Single-arm Clinical Study of HAIC Combined With Apatinib and Camrelizumab in the Treatment of Unresectable MTM HCC(CCGLC-010) | unknown | Phase 2 | 38 | Wan-Guang ZhangOTHER | 1 | Dec 19, 2023 | clinicaltrials |
| NCT02969083 | Feasibility of Neo-adjuvant Versus Adjuvant Chemotherapy in Upper Tract Urothelial Carcinoma(URANUS) | unknown | Phase 2 | 200 | The European Uro-Oncology GroupOTHER | 3 | Dec 18, 2023 | clinicaltrials |
| NCT03812393 | Evaluating the Efficacy of Neratinib on Live Cell HER2 Signaling Transduction Analysis Positive Triple Negative Breast(FACT-2) | unknown | Phase 2 | 27 | West Cancer CenterOTHER | 1 | Dec 18, 2023 | clinicaltrials |
| NCT03935256 | Adjuvant Sequential & Concurrent CarboTaxol + Radiotherapy for High Risk Endometrial Cancer | unknown | Phase 2 | 24 | Loyola UniversityOTHER | 1 | Dec 18, 2023 | clinicaltrials |
| NCT04197687 | TPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage II-III Breast Cancer in Patients With Residual Disease After Chemotherapy and Surgery | unknown | Phase 2 | 480 | Academic and Community Cancer Research UnitedOTHER | 1 | Dec 18, 2023 | clinicaltrials |
| NCT05150236 | EVOLUTION: 177Lu-PSMA Therapy Versus 177Lu-PSMA in Combination With Ipilimumab and Nivolumab for Men With mCRPC(ANZUP2001) | unknown | Phase 2 | 93 | Australian and New Zealand Urogenital and Prostate Cancer Trials GroupOTHER | 1 | Dec 15, 2023 | clinicaltrials |
| NCT06172634 | A Single-center Clinical Study to Evaluate the Safety and Efficacy of Autologous Bone Marrow-derived DCs(CellgramDC-WT1) and Immune Checkpoint Inhibitors in Patients With Metastatic Pancreatic Cancer Who Have Failed First-line or More Standard Chemotherapy(DICI_PC) | unknown | Phase 1 / Phase 2 | 10 | Soonchunhyang University HospitalOTHER | 0 | Dec 15, 2023 | clinicaltrials |
| NCT05577364 | Selinexor in Combination With R-CHOP Followed by Selinexor Maintenance for Untreated EBV-positive DLBCL Patients | unknown | Phase 1 / Phase 2 | 54 | Sun Yat-sen UniversityOTHER | 1 | Dec 14, 2023 | clinicaltrials |
| NCT06168552 | Fluorescent Navigation Technology in Radical Resection of Pancreatic Cancer(CISPD-6) | unknown | Phase 1 / Phase 2 | 20 | Zhejiang UniversityOTHER | 0 | Dec 13, 2023 | clinicaltrials |
| NCT03617666 | Avelumab in the Frontline Treatment of Advanced Classical Hodgkin Lymphoma - a Window Study(AVENuE) | unknown | Phase 2 | 49 | University College, LondonOTHER | 2 | Dec 12, 2023 | clinicaltrials |
| NCT04407741 | Phase Ⅰ/Ⅱ Study of SHR2554 in Combination With SHR1701 in Patients With Advanced Solid Tumors and B-cell Lymphomas | unknown | Phase 1 / Phase 2 | 100 | Chinese PLA General HospitalOTHER | 1 | Dec 12, 2023 | clinicaltrials |
| NCT06029036 | A Phase II Neoadjuvant Study of Darolutamide Plus ADT in Men With Localized Prostate Cancer | unknown | Phase 2 | 53 | Peking University First HospitalOTHER | 1 | Dec 12, 2023 | clinicaltrials |
| NCT05432934 | Transversus Abdominis Plane Blocks With and Without Dexamethasone(TAP-DEX) | unknown | Phase 1 / Phase 2 | 60 | University of SaskatchewanOTHER | 1 | Dec 7, 2023 | clinicaltrials |
| NCT05578287 | RC48 Plus Tislelizumab, Low-dose Capecitabine and Celecoxib for HER2-positive Metastatic Colorectal Cancer(DETECT) | unknown | Phase 2 | 29 | Sun Yat-sen UniversityOTHER | 1 | Dec 7, 2023 | clinicaltrials |
| NCT06153368 | Cadonilimab Plus mFOLFIRINOX as Conversion Therapy in LAPC | unknown | Phase 2 | 30 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Dec 7, 2023 | clinicaltrials |
| NCT06161272 | Fluzoparib With or Without Apatinib in Platinum-sensitive Relapsed Ovarian Cancer Previously Treated With PARPi | unknown | Phase 2 | 80 | Guangxi Medical UniversityOTHER | 1 | Dec 7, 2023 | clinicaltrials |
| NCT01811394 | Ion Irradiation of Sacrococcygeal Chordoma(ISAC) | unknown | Phase 2 | 100 | Heidelberg UniversityOTHER | 1 | Dec 6, 2023 | clinicaltrials |
| NCT03620032 | Study of Re-irradiation at Relapse Versus RT and Multiple Elective rt Courses(DIPG) | unknown | Phase 2 | 54 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | Dec 6, 2023 | clinicaltrials |
| NCT04877275 | ATG-010(Selinexor) in Combination With Chemotherapy in RRMM | unknown | Phase 2 | 50 | Chunyan Sun, MDOTHER | 1 | Dec 6, 2023 | clinicaltrials |
| NCT05820906 | Cadonilimab Plus Regorafenib and Gem-Cis Chemotherapy in Advanced Biliary Tract Cancer | unknown | Phase 2 | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Dec 6, 2023 | clinicaltrials |
| NCT06156878 | PD-1 Inhibitor Plus Anti-EGFR Therapy And Radiotherapy in Locally Advanced NPC Resistant to Induction Chemotherapy | unknown | Phase 2 | 41 | Fudan UniversityOTHER | 1 | Dec 5, 2023 | clinicaltrials |
| NCT06156891 | PD-1 Inhibitor Based Induction Chemotherapy Followed by De-escalation Protocols in OPSCC | unknown | Phase 2 | 60 | Fudan UniversityOTHER | 1 | Dec 5, 2023 | clinicaltrials |
| NCT02004275 | Pomalidomide and Dexamethasone With or Without Ixazomib in Treating Patients With Relapsed Multiple Myeloma | unknown | Phase 1 / Phase 2 | 118 | Alliance for Clinical Trials in OncologyOTHER | 1 | Dec 1, 2023 | clinicaltrials |
| NCT05280275 | A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Transplant Ineligible | unknown | Phase 1 / Phase 2 | 36 | Hellenic Society of HematologyOTHER | 1 | Dec 1, 2023 | clinicaltrials |
| NCT05523609 | Vitamin D and Calcium Supplementation in Breast Cancer | unknown | Phase 2 / Phase 3 | 40 | Tanta UniversityOTHER | 1 | Dec 1, 2023 | clinicaltrials |
| NCT06154109 | Comparative Efficacy of Xiaopi Granules and Decoction in Triple-negative Breast Cancer: a Randomized Controlled Trial | unknown | Phase 2 | 90 | Zhiyu WangOTHER | 0 | Dec 1, 2023 | clinicaltrials |
| NCT03729687 | Short Course Radiation Therapy Followed by Pre-operative Chemotherapy and Surgery in High-risk Rectal Cancer(LARCT-US) | unknown | Phase 2 | 280 | Uppsala UniversityOTHER | 1 | Nov 30, 2023 | clinicaltrials |
| NCT06151249 | Evaluate the Meritup Oral Solution to Decrease Fatigue in Metastatic Breast Cancer Patients Receiving Chemotherapy | unknown | Phase 2 | 32 | Chung Shan Medical UniversityOTHER | 0 | Nov 30, 2023 | clinicaltrials |
| NCT02935205 | Enzalutamide and Indomethacin in Treating Patients With Recurrent or Metastatic Hormone-Resistant Prostate Cancer | unknown | Phase 1 / Phase 2 | 38 | Mamta ParikhOTHER | 1 | Nov 29, 2023 | clinicaltrials |
| NCT03193281 | KISS Study: Kinase Inhibition With Sprycel Start up(KISS) | unknown | Phase 2 | 91 | University of Auckland, New ZealandOTHER | 1 | Nov 29, 2023 | clinicaltrials |
| NCT03614858 | CD19/CD22-targeted Chimeric Antigen Receptor Engineered T Cell (CART) in B-Cell Acute Lymphoblastic Leukemia. | unknown | Phase 1 / Phase 2 | 20 | Shanghai Unicar-Therapy Bio-medicine Technology Co.,LtdINDUSTRY | 1 | Nov 29, 2023 | clinicaltrials |
| NCT03896854 | CART-19 T Cell in CD19 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML) | unknown | Phase 1 / Phase 2 | 15 | Shanghai Unicar-Therapy Bio-medicine Technology Co.,LtdINDUSTRY | 1 | Nov 29, 2023 | clinicaltrials |
| NCT04257175 | CAR-T CD19 for Acute Myelogenous Leukemia With t 8:21 and CD19 Expression | unknown | Phase 2 / Phase 3 | 10 | Sheba Medical CenterOTHER_GOV | 1 | Nov 28, 2023 | clinicaltrials |
| NCT04989335 | Bisantrene Combination for Resistant AML | unknown | Phase 2 | 29 | Sheba Medical CenterOTHER_GOV | 1 | Nov 28, 2023 | clinicaltrials |
| NCT05262335 | Anlotinib Plus Chemotherapy as First-line Therapy for Gastrointestinal Tumor Patients With Unresectable Liver Metastasis (ALTER-G-001)(ALTER-G-001) | unknown | Phase 2 | 116 | Ruijin HospitalOTHER | 1 | Nov 28, 2023 | clinicaltrials |
| NCT05583175 | Venetoclax Plus RIC Regimen Allo-HSCT for Elderly Patients With High-risk Myeloid Malignancies | unknown | Phase 2 | 50 | Xianmin Song, MDOTHER | 1 | Nov 28, 2023 | clinicaltrials |
| NCT06146985 | Famitinib in Combination With Adebrelimab for the Treatment of Advanced Thyroid Cancer | unknown | Phase 2 | 67 | Ruijin HospitalOTHER | 0 | Nov 28, 2023 | clinicaltrials |
| NCT04089215 | CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Non-Hodgkins Lymphoma | unknown | Phase 2 | 82 | Shanghai Ming Ju Biotechnology Co., Ltd.INDUSTRY | 1 | Nov 24, 2023 | clinicaltrials |
| NCT05329025 | A Study of QL1706 Combined With Chemotherapy in Advanced Non-small Cell Lung Cancer | unknown | Phase 2 | 100 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Nov 24, 2023 | clinicaltrials |
| NCT05588219 | Tislelizumab Combined With Concurrent Chemoradiotherapy for Locally Advanced Cervical Cancer | unknown | Phase 2 | 30 | Yong Zhang,MDOTHER | 1 | Nov 24, 2023 | clinicaltrials |
| NCT03906669 | A Window of Opportunity Study of Pre-operative Endocrine Therapy With and Without Prometrium in Postmenopausal Women With Early Stage Breast Hormone Receptor Positive (HR+) Human Epidermal Receptor 2 Negative (HER2-) Breast Cancer.(WinPro) | unknown | Phase 2 | 200 | St Vincent's HospitalOTHER | 1 | Nov 22, 2023 | clinicaltrials |
| NCT05576272 | A Phase II/III Trial to Evaluate the Efficacy and Safety of QL1706 in Patients With Nasopharyngeal Carcinoma | unknown | Phase 2 / Phase 3 | 460 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Nov 22, 2023 | clinicaltrials |
| NCT05580445 | Safety, Pharmacokinetics and Efficacy of CT-707, Toripalimab and Gemcitabine in Advanced Pancreatic Cancer | unknown | Phase 1 / Phase 2 | 114 | Shouyao Holdings (Beijing) Co. LTDOTHER | 1 | Nov 22, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Dec 27, 2023source: clinicaltrials